IBT vs. CGL, JUSC, ASLI, BGUK, MTE, MNL, CCJI, RECI, HHI, and GRID
Should you be buying International Biotechnology stock or one of its competitors? The main competitors of International Biotechnology include Castelnau Group (CGL), JPMorgan US Smaller Companies (JUSC), abrdn European Logistics Income (ASLI), Baillie Gifford UK Growth Trust (BGUK), Montanaro European Smaller (MTE), Manchester & London (MNL), CC Japan Income & Growth Trust (CCJI), Real Estate Credit Investments (RECI), Henderson High Income (HHI), and Gresham House Energy Storage (GRID). These companies are all part of the "asset management" industry.
International Biotechnology (LON:IBT) and Castelnau Group (LON:CGL) are both small-cap financial services companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, community ranking, earnings and media sentiment.
52.1% of International Biotechnology shares are held by institutional investors. Comparatively, 71.4% of Castelnau Group shares are held by institutional investors. 4.7% of International Biotechnology shares are held by insiders. Comparatively, 12.6% of Castelnau Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
International Biotechnology has a beta of 0.18, meaning that its stock price is 82% less volatile than the S&P 500. Comparatively, Castelnau Group has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500.
In the previous week, International Biotechnology and International Biotechnology both had 1 articles in the media. International Biotechnology's average media sentiment score of 0.27 beat Castelnau Group's score of 0.00 indicating that International Biotechnology is being referred to more favorably in the media.
International Biotechnology has a net margin of 84.61% compared to Castelnau Group's net margin of 0.00%. International Biotechnology's return on equity of 15.33% beat Castelnau Group's return on equity.
International Biotechnology has higher revenue and earnings than Castelnau Group. Castelnau Group is trading at a lower price-to-earnings ratio than International Biotechnology, indicating that it is currently the more affordable of the two stocks.
International Biotechnology received 41 more outperform votes than Castelnau Group when rated by MarketBeat users. Likewise, 77.71% of users gave International Biotechnology an outperform vote while only 42.04% of users gave Castelnau Group an outperform vote.
Summary
International Biotechnology beats Castelnau Group on 11 of the 14 factors compared between the two stocks.
Get International Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for IBT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
International Biotechnology Competitors List
Related Companies and Tools
